|Car T-Cell Therapy: How It Works|
The approval Wednesday allows a process known as CAR T-cell therapy to be used in children or young adults fighting an often fatal recurrence of the most common childhood cancer - B-cell acute lymphoblastic leukemia.
And it clears the way for a new approach to fighting cancer by harnessing the body's immune system - a long-sought goal of medical researchers.
"This is a dream come true", says Henry Fung, MD, director of the Fox Chase Cancer Center-Temple University Hospital Bone Marrow Transplant Program. "It's now limited to one disease in children only, but that platform potentially can benefit a lot of different types of cancer patients, particularly blood cancer patients".
'A New Frontier'
FDA Commissioner Scott Gottlieb, MD, called the approval of the therapy - brand named Kymriah - a "new frontier in medical innovation".
In a news conference on Wednesday, Gottlieb said the FDA had 76 active investigational new drug applications related to CAR T-cell products, and more than 500 for gene therapy products are being studied for a variety of ailments, ranging from genetic disorders to autoimmune diseases, diabetes, cancer, and HIV.
Fung, who's also vice chairman of hematology/oncology at Fox Chase, says the treatment could help patients beat back an illness that has resisted conventional treatments like chemotherapy and radiation, leaving them facing death. "This is the breakthrough of the century," he says.
An acute leukemia doctor said that the newly approved therapy represents a first step for a new way of treating cancer. "If it can bring this kind of paradigm to other types of cancers, that's really where I think the larger implications are", she says.